Aegis Reiterates “Buy” Rating for SciClone Pharmaceuticals (SCLN)
In other SciClone Pharmaceuticals news, Director Nancy T. Chang purchased 25,040 shares of the stock on the open market in a transaction dated Friday, August 15th. The stock was purchased at an average cost of $6.00 per share, with a total value of $150,240.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of SciClone Pharmaceuticals (NASDAQ:SCLN) traded up 4.07% during mid-day trading on Friday, hitting $6.90. 121,656 shares of the company’s stock traded hands. SciClone Pharmaceuticals has a 1-year low of $4.24 and a 1-year high of $7.02. The stock has a 50-day moving average of $5.45 and a 200-day moving average of $4.99. The company has a market cap of $352.4 million and a price-to-earnings ratio of 15.79.
SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its earnings results on Monday, August 11th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.10. The company had revenue of $32.50 million for the quarter, compared to the consensus estimate of $33.40 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, analysts predict that SciClone Pharmaceuticals will post $0.49 earnings per share for the current fiscal year.
SciClone Pharmaceuticals, Inc (NASDAQ:SCLN) is a specialty pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.